Phase 1 × Completed × Leukemia, Myelomonocytic, Juvenile × Clear all AML/MDS/JMML
Phase 1 Completed
18 enrolled
Yttrium-90 Anti CD66 Monoclonal Antibody in Childhood Relapsed/Refractory Leukaemia
Phase 1 Completed
9 enrolled
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
Phase 1 Completed
133 enrolled
Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy
Phase 1 Completed
20 enrolled
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
Phase 1 Completed
49 enrolled
Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia
Phase 1 Completed
60 enrolled
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
Phase 1 Completed
45 enrolled
Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies
Phase 1 Completed
48 enrolled
Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer
Phase 1 Completed
Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant
Phase 1 Completed
18 enrolled
Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency Disease
Phase 1 Completed
21 enrolled
Tipifarnib in Treating Young Patients With Refractory Leukemia
Phase 1 Completed
Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders
Phase 1 Completed
70 enrolled